Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653374 | 0.80 | KCNMA1 (0.48) | KDM4EALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL29609758 | 0.77 | NSD2 (0.60) | KDM4EGAANSD2ALDH1A1MEN1 | |
| SCHEMBL30310556 | 0.77 | HRH4 (0.56) | KDM4EALDH1A1MEN1USP2HPGD | |
| SCHEMBL28399059 | 0.77 | NSD2 (0.60) | KDM4EGAANSD2ALDH1A1MEN1 | |
| SCHEMBL29063451 | 0.77 | HRH4 (0.56) | KDM4EALDH1A1MEN1USP2HPGD | |
| SCHEMBL7942068 | 0.77 | HRH4 (0.57) | ALDH1A1MEN1USP2HPGDKMT2A | |
| SCHEMBL30494484 | 0.76 | HPGD (0.46) | KDM4ENSD2ALDH1A1MEN1USP2 | |
| SCHEMBL28064535 | 0.76 | HPGD (0.46) | KDM4ENSD2ALDH1A1MEN1USP2 | |
| SCHEMBL2662137 | 0.76 | SLC40A1 (0.54) | GAAMEN1KMT2ATDP1 | |
| SCHEMBL3626110 | 0.75 | HPGD (0.53) | KDM4ENSD2ALDH1A1MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618758-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2023-04-04 | — | — | US | disclosed |
| US-20210032266-A1 | Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating A Patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2021-02-04 | — | — | US | disclosed |
| US-10844075-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-11-24 | — | — | US | disclosed |
| US-10385064-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180105536-A1 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-04-19 | — | — | US | disclosed |
| EP-2670244-B1 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | UNIV HOLY GHOST DUQUESNE (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9732090-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160009731-A1 | Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating a Patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-01-14 | — | — | US | disclosed |
| US-9139590-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2670244-A2 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | Duquesne University of The Holy Spirit (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20120264768-A1 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2012-10-18 | — | — | US | disclosed |
| WO-2012106522-A2 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032266-A1 | Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating A Patient | TK1, UACA, DSTYK | KDM4E 4436/4885GAA 3191/4885NSD2 4209/4885 |
| US-11618758-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | TK1, UACA, DSTYK | KDM4E 4436/4885GAA 3191/4885NSD2 4209/4885 |
| US-20180105536-A1 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | TK1, UACA, DSTYK | KDM4E 4436/4885GAA 3191/4885NSD2 4209/4885 |
| US-20120264768-A1 | BICYCLIC AND TRICYCLIC PYRIMIDINE TYROSINE KINASE INHIBITORS WITH ANTITUBULIN ACTIVITY AND METHODS OF TREATING A PATIENT | TK1, UACA, DSTYK | KDM4E 4436/4885GAA 3191/4885NSD2 4209/4885 |
| US-10385064-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | TK1, UACA, DSTYK | KDM4E 4436/4885GAA 3191/4885NSD2 4209/4885 |
| US-10844075-B2 | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient | TK1, UACA, DSTYK | KDM4E 4436/4885GAA 3191/4885NSD2 4209/4885 |
| US-20160009731-A1 | Bicyclic and Tricyclic Pyrimidine Tyrosine Kinase Inhibitors with Antitubulin Activity and Methods of Treating a Patient | TK1, UACA, DSTYK | KDM4E 4436/4885GAA 3191/4885NSD2 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.